Respicardia Stock

respicardia.comHealthcareFounded: 2006Funding to Date: $153.45MM

Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health.

Register for Details

For more details on financing and valuation for Respicardia, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Bonnie Labosky
Chief Executive Officer, Board Member & President
Peter Sommerness
Chief Executive Officer
Timothy Hauch
Chief Financial Officer
Frank Piskolich JD
General and IP Counsel
Linda Nelson
Vice President, Clinical Affairs
Todd Goblish
Vice President, Research & Development
Robin Germany MD
Chief Medical Officer

Board Members

Edward Andrle
Sorin
Kevin Wasserstein
Versant Venture Management
Kirk Nielsen
Versant Venture Management
Kristine Johnson
Affinity Capital Management
Scott Ward
Thomas Weldon
Accuitive Medical Ventures
Wilfred Jaeger MD
Three Arch Partners
William Abraham MD
Zack Scott MD
Revelation Partners

Other companies like Respicardia in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$2.51B
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$453MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$1.61B
Sector
Last Round Est. Valuation
$355.29MM
Sector
Last Round Est. Valuation
$8.18B
Sector
Last Round Est. Valuation
$263MM

News

Respicardia Inc. has received a $20 million investment from Sorin Group and sold select European distribution rights for its implantable sleep apnea device to the Italian medical-device company.
Sorin GroupĀ (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.